转移性黑色素瘤患者个体化管理策略：管理式医疗视角
Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
作者信息
Goldstein Daniel A, Zeichner Simon B
出版信息
Am J Manag Care. 2015 Sep;21(10 Suppl):S234-41.
The management of metastatic melanoma has been revolutionized in recent years with the development of both targeted therapy and immunotherapy. Although potentially extending the life expectancy for patients, these therapies also significantly increase the healthcare expenditure. In this paper, we review the monthly costs for drugs approved by the FDA since 2011. Additionally, factors that affect the cost, such as dosing strategies, biomarkers, combination therapies, and political/legislative issues, will be discussed.
近年来，随着靶向治疗和免疫治疗的发展，转移性黑色素瘤的治疗发生了革命性变化。尽管这些疗法有可能延长患者的预期寿命，但也显著增加了医疗费用。在本文中，我们回顾了自2011年以来美国食品药品监督管理局（FDA）批准的药物的月度费用。此外，还将讨论影响成本的因素，如给药策略、生物标志物、联合疗法以及政治/立法问题。
Zotero 插件